FoldaxAnnouncing its surgical polymer valve---TRIAThe first patient has had the implant for over five years. This is the first polymer valve in human history to have been implanted for more than five years.
Robert Murley is the first to participateTRIAClinical research patients. No one knows about a revolutionary product.TRIAAs for the clinical effects, Robert Murley can show great courage.
Fortunately,TRIAPerformance and clinical outcomes justify Robert Murley's courage post-surgery.TRIADemonstrated superior performance. Shortly after the surgery, Robert Murley was able to stop taking anticoagulant medications, and his quality of life significantly improved. He can live a normal life, even engaging in strenuous physical activities such as running and weightlifting.Based on the currently published clinical data, it can be confirmed thatTRIAIt is currently the best polymer valve. Of course, many other companies are involved in the development of polymer valves, but these companies provide very little clinical research data, and the scale of their clinical studies is also small. It is difficult to judge the true clinical efficacy of these products based on the publicly available clinical research data.However, as more clinical research data on other polymer valves becomes available, the performance differences between polymer valves will be fully distinguished.。
TriaAdoptFoldaxThe Revolutionary Polymer Material Developed ----LifePolymer，Lifepolymer not only has performance similar to biological valves, but also some properties superior to biological valves., such asExcellent tissue compatibility, excellent mechanical properties, long service life.LifepolymerIs a uniqueSilicone Polyurethane, withThree-phase morphology, high resistance to creep deformation, and ease of forming films through solvent casting.Physical and Chemical Properties of Lifepolymer- Number-average molecular weight (Mn) is approximately 120,000 Da (GPC tested).
- Ultimate Tensile Strength: ≥30MPa
- MoveStateModulus:25-35MPa
Lifepolymer also changed the valve manufacturing process from purely handcrafted to automated production, which not only reduced costs but also made the valve quality more reliable.Will be a numberMillions of patients with aortic, mitral, and tricuspid valve diseases have been treated.More economical, safer, and effective treatment。At the same timeTriaIt is also the first heart valve manufactured by a robotic process. Therefore, its polymer leaflets can be consistently produced with precise thickness, designed to achieve predictable valve performance and last a lifetime for the patient.
- AdoptAn advanced biopolymer material---LifePolymer，The valve is more durable., without the need to apply any animal tissue;
- Will reduce or eliminate the need for lifelong anticoagulant medication；
- Providing a larger opening area than traditional valves, establishingSimilar hemodynamics and blood flow to human heart valves；
- Able toVia catheter or surgical procedureMethod for treating heart valve disease;
- AdoptMechanized Production and Manufacturing，Better Precision and Quality Control, while eliminating the uncontrollability of manual production;
- With more competitive economic value;
FoldaxAn innovative medical device company located in Salt Lake City, Utah, which designs and developsTria heart valvesPlatformIs the global firstPolymer heart valve platform. This platform technology can be applied to valve replacement for aortic, mitral, and tricuspid valve diseases.FoldaxThe PurposeIt is to revolutionize the structural heart market by expanding patient access, improving product performance, and significantly reducing costs through new materials, design, and manufacturing technologies.。
